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Abstract 
The aim of the article is to describe the prin-
cipal findings among patients with M.tubercu-
losis  and  M.  bovis CNS  infection.  Mycoba  -
cterium tuberculosis is one of the most com-
mon infectious agents that cause death and
neurological sequelae around the world. Most
of the complications of CNS TB can be attrib-
uted to a delay in the diagnosis. Unfortu  nately,
there are no specific diagnostic tools to sup-
port an early diagnosis. Other prognostic fac-
tors different from delay in treatment have not
been identified. Clinical, radiological and labo-
ratory characteristics were analyzed retrospec-
tively from the medical files of all the patients
admitted with the diagnoses of tuberculosis.
Of 215 patients admitted with systemic tuber-
culosis, 64 (30%) had a neurological infection.
Positive  cultures  were  found  in  54  (84%)
cases, 18 (33%) in the CSF and the rest in
other  fluids  or  tissues.  Adenosin  deaminase
(ADA) enzyme determination was more sensi-
tive than M. tuberculosis PCR in the CSF for
supporting an early diagnosis. In addition to a
later clinical stage and treatment lag, positive
CSF cultures (P=0.001) and the presence of M.
bovis (P=0.020) were prognostic factors for a
worse outcome. Neither older age, the pres-
ence  of  tuberculomas  versus  meningeal
enhancement, or HIV co-infection, was associ-
ated to a worse prognosis. The isolation of M.
bovis subspecies was more common that previ-
ously reported, and it was associated to the
development  of  parenchymal  lesions
(P=0.032) when compared to M. tuberculosis.
In  this  study,  positive  CSF  cultures  for  M.
tuberculosis and further identifying M. bovis
species were additional prognostic factors for
worse outcome. Positive cultures in systemic
fluids other than CSF, even when the patient
had no obvious systemic manifestations, and
ADA determination in the CSF were notewor-
thy diagnostic tools for the diagnosis.
Introduction
Mycobacterium  tuberculosis  is  one  of  the
most  common  infectious  agents  that  cause
death  and  neurological  sequelae  around  the
world. Only in Mexico, there are 40,000 cases
of active tuberculosis, and around 2500 cases
are multi-drug resistant.1 It is estimated that
the central nervous system (CNS) is involved
in  5-10%  of  the  extra-pulmonary  cases,
accounting  for  1.3%  of  the  total  number  of
cases.2 The diagnosis of CNS tuberculosis is
challenging, mostly because the initial symp-
toms  may  be  identical  to  bacterial  or  viral
meningitis. As a result, most of the patients
receive  multiple  incorrect  treatments,  which
may  improve  the  symptoms  temporary,  but
lengthens the time for diagnosis and worsens
the prognosis. 
Most of the complications of CNS tuberculo-
sis can be attributed to the direct result of a
delay in the diagnosis, with an estimated 3.7-
fold risk for a fatal outcome when the treat-
ment is begun after 5 days of the initiation of
symptoms.3 Unfortunately, there are no specif-
ic diagnostic tools to support an early diagno-
sis. Isolating M. tuberculosis from CSF cultures
is the only definite diagnostic method, but it
has a very low sensitivity and becomes positive
up to 6 to 8 weeks later. Other ancillary tests
for the diagnosis of CNS tuberculosis are less
specific, and most have been extrapolated for
the diagnosis of pulmonary tuberculosis.4 In
this study we aimed to identify the most com-
mon clinical, radiographic, and laboratory find-
ings  in  patients  with  tuberculosis  and  CNS
involvement in the Mexican population, and
we compared them to similar series from the
literature. 
Materials and Methods
We  reviewed  retrospectively  the  medical
files of all patients with the diagnosis of pul-
monary or extra-pulmonary tuberculosis, CNS
tuberuculosis  and  tuberculous  meningitis
admitted  to  a  tertiary-care  level  hospital  in
Mexico City from 1999 to 2009. Diagnosis of
CNS tuberculosis was done according to inter-
national recognized clinical, radiological and
laboratory criteria.5 Clinical criteria included
fever, headache, and nucal rigidity. Laboratory
criteria included CSF pleocytosis greater than
10 cells per mm3 or proteins above 30 mg per
deciliter with negative bacterial or fungal CSF
cultures. Radiological criteria included hydro-
cephalus,  tuberculomas,  cerebral  infarcts,
meningeal enhancement, or exudates. In addi-
tion, the results of the following tests were rec-
ollected:  i)  presence  of  mycobacteria  in  the
CSF or cerebral tissue; ii) polymerase chain
reaction (PCR) tests for M. tuberculosis in the
CSF; iii) microscopic examination of the CSF;
iv) cultures or staining of other corporal fluids
such as gastric aspirate; urine, feces, pleuritic
fluid or ascitis; v) cultures or stain of non-cere-
bral tissues; vi) tuberculin skin test (PPD). 
A definite diagnosis of meningeal tuberculo-
sis was done when a positive culture or stain-
ing for M. tuberculosis was present in the CSF
or cerebral tissue. A probable diagnosis was
done when the clinical picture was compatible,
in  addition  to  positive  cultures  or  stains  in
other  non-CNS  fluids  or  tissues.  A  possible
diagnosis  was  performed  when  there  was  a
suggestive clinical picture, history of systemic
tuberculosis,  and  improvement  with  anti-
tuberculosis treatment.5-6
CSF  and  other  corporal  fluids  and  tissues
were processed in all the patients with a clini-
cal suspicion of tuberculosis according to the
clinical criteria and the decision of the physi-
cian in charge. All clinical specimens were cul-
tured  in  enrichment  medias  for  aerobic  and
anaerobic bacteria, mycobacteria and fungus.
After the Ziehl-Neelsen stain, all the samples
were  cultured  in  solid  media  (Löwenstein-
Jensen  modified  with  asparagine)  (DIFCO,
Mex), and in liquid media Bactec 12B or MGIT
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according  to  the  manufacturer  instructions.
The cultures were identified by DNA samples
(Geneprobe, San Diego, CA, USA) or with the
traditional biochemical methods. The drug sus-
ceptibility essays to first line ATB drugs were
done through the radiometric method Bactec
460 TB (Becton Dickinson). The PCR was nest-
ed with the following oligonucleic acids of the
insertion  sequence  IS6110;  the  external
oligonucleids  GO15´CGGGACCACCCGCG-
GCAAAGCCCGCAGGAC 3´and GO2 5´CATCGTG-
GAAGCGACCCGCCAGCCCAGGAT 3 produced a
fragment of 219pb; the internal oligonucleids
Tb4 5´CCTGCGAGCGTAGGCGTCGG 3´ and Tb5
5´CTCGTCCAGCGCCGCTTCGG  3´  that  pro-
duced a fragment of 123 pb. 
Clinical  manifestations  were  classified
according  to  the  British  Medical  Research
Council  Criteria3,5,6 in  three  stages:  Stage  I
(early):  non-specific  symptoms,  the  patient
was conscious and without neurological signs;
Stage II (intermediate): there was altered men-
tal status but not comatose, or there were focal
neurological  signs  such  as  cranial  nerve
involvement  or  hemiparesis;  Stage  III
(advanced): patients were lethargic or coma-
tose or had severe neurologic alterations such
as seizures or involuntary movements.
After initiating anti-tuberculosis treatment
and steroids, we registered all new neurologi-
cal complications including the new formation
or  enlargement  of  cerebral  lesions,  develop-
ment of hydrocephalus, new onset of seizures
or  cranial  nerve  paralysis,  occurrence  of
intracranial  hypertension,  coma,  or  death.
Clinical outcome at the end of the hospitaliza-
tion period was registered using the modified
Rankin Scale where 1 stands for the absence of
neurologic complications, 2 for the presence of
non-incapacitating neurologic sequelae, 3 for
the  presence  of  incapacitating  neurologic
sequelae, and 4 for death. 
All of the clinical, laboratory and radiological
characteristics were analyzed through univari-
ate  and  multivariate  logistic  regression  in
patients with good outcome and bad outcome,
using as final parameters death, non-incapaci-
tating, and incapacitating neurologic sequelae.
The Fisher’s Exact test was used for the cate-
gorical analysis and the Wilcoxon Test for the
non-parametric analysis. SPSS version 16 for
Mac  was  used  for  the  statistical  analysis.  A
value of P=0.05 or less was used as statistical-
ly  significant.  This  retrospective  study  was
approved by the IRB ethical standards.
Results
Epidemiological characteristics
From 1999 to 2009, 215 patients were diag-
nosed with systemic tuberculosis; of them, 64
(30%)  had  clinical  manifestations  of  CNS
involvement and were included in the study.
Fifty patients (78%) were men. Mean age at
onset was 45 years old (range 21-83). Fourteen
patients  (22%)  were  HIV  positive.  Other
comorbidities  varied  widely.  Only  four  (6%)
patients came from the north states, including
two from the United States, and two from the
south states. The rest came from the central
states of the country. Diagnosis was definite in
44 patients (68.8%), probable in 14 (21.9%),
and possible in 6 (9.4%).
Characteristics at entry
Of the 64 patients with CNS tuberculosis,
the neurologic symptoms were the only mani-
festation of the disease in 44% of the patients,
38% had neurologic and systemic manifesta-
tions at onset, and only 18% had neurological
involvement after more than one month of the
diagnosis of systemic tuberculosis. The mean
interval  of  time  between  the  initial  clinical
manifestations, and hospital admission was 2
months (±6; 0-36 days). 
Clinical course
Forty  patients  (62%)  had  meningitis  or
menigoencephalitis as the initial presentation,
20 (31%) had focal neurological signs sugges-
tive of tuberculomas or stroke, and the rest had
a combination of both presentations. Sixty-six
percent of the patients had a Glasgow Coma
Score (GCS) below 15 points and one third of
the  patients  had  meningeal  signs.  Nineteen
patients  (30%)  had  seizures  at  onset  and  9
(14%) had stroke. According to the MRC crite-
ria,  11  patients  (17%)  were  in  Stage  I,  26
(49%) in Stage II and 27 (43%) in Stage III. 
Laboratory findings
Intradermal purified protein (PPD) reaction
was assessed in 27 patients and had a positive
value of 15 to 80 mm in 7 (25%). Ziehl-Neelsen
stains were positive in 8 cases, three in the
CSF, two in stools, and the rest in miscella-
neous tissues (sputum, ascites, lymph nodes,
and  cerebral  tissue).  Positive  cultures  were
found in 54 (84%) cases, 18 in the CSF, 14 in
the pulmonary biopsies, and the rest in other
tissues or fluids (lymph nodes, cerebral biopsy,
peritoneal fluid, urine, eye, bone marrow and
bone biopsies). Forty-six cultures were posi-
tive for M. tuberculosisand 8 cultures were fur-
ther identified as M. bovis. Twenty-five (39%)
patients  had  hyponatremia  (Na<130mEq)  at
entry,  and  4  (6.25%)  developed  it  later
(SIADH).
Radiographic findings
All the patients had an initial brain image
performed; three patients had a CT scan, 10
patients had an MRI, and 51 patients had CT
scan and MRI. Initial findings were parenchy-
mal  lesions  (tuberculomas)  in  21(32%),
meningeal enhancement in 13 (20%), hydro-
cephalus in 6 (9.4%), and stroke in 9 (14%).
Follow-up MRI was performed in 28 patients,
on those, new findings were seen in 20(83%)
patients;  further  development  of  stroke  was
seen  in  6  (21.4%),  of  hydrocephalus  in  6
(21.4%),  of  new  parenchymal  lesions  in  5
(17.8%), and of pachymeningitis in 3 (10.7%).
There was improvement in 4 cases and similar
findings as the initial image in the rest. No
spinal  cord  image  was  performed  in  our
patients  in  search  of  arachnoiditis  or
intraspinal tuberculomas.
Lumbar puncture
All the patients had at least one LP. Initial
CSF  analysis  was  abnormal  in  55  (85%)
patients. Subsequent CSF analysis was done in
33 patients, with a time interval between one
and 270 days. The results are shown in Table 1.
CSF PCR for M. tuberculosis was positive in 22
(55%) of 40 patients in which the test was per-
formed.  Of  the  26  patients  with  adenosin-
deaminse (ADA) enzyme determination in the
CSF, 25 (96%) had a positive result. ADA con-
centrations varied between 1 and 50 UI, with a
mean and median of 8 UI. 
Treatment
All the patients were hospitalized. The time
interval between the hospital admission and
the initiation of treatment was 21 days (R:0-5-
540, median 9). Thirty-seven patients (57.5%)
received empirical treatment with the combi-
nation of a third-generation cephalosporin and
vancomycin for suspicion of bacterial meningi-
tis. Twenty-nine patients (45%) had acyclovir
or amphotericin B added to the previous regi-
men before initiating anti-tuberculosis treat-
ment.  Fifty  patients  (78%)  received  steroids
before the anti-tuberculosis (ATb) treatment
for  the  suspicion  of  bacterial  meningitis  or
because  there  were  already  prescribed  for
other reasons. All the patients were initiated
with four ATb medications (rifampicin, isoni-
azid,  pyrazinamide  and  ethambutol)  for  at
least two months before receiving the mainte-
nance phase. Mean time of ATb therapy was
11.9±7  months.  Fourteen  patients  (21%)
required a ventriculo-peritoneal shunt to treat
hydrocephalus.
Prognostic factors and outcome
Forty-five patients (71.4%) had a bad out-
come (Rankin 2, 3 and 4). Twenty-two patients
(34%) suffered permanent neurologic seque-
lae  and  23  (35%)  died.  Twenty-five  patients
(39%)  had  neurological  deterioration  during
the  hospitalization  between  the  third  and
130th days (median 30 days). Thirteen (20%)
patients had new or enlarged cerebral lesions
during treatment. Ten patients (15%) devel-
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(19%), and stroke in 10 (15.6%). Of patients
with  a  bad  outcome,  12  (18.8%)  were  not
receiving steroids at the time, steroids were
being tapered-down in one, and the rest had
them  at  optimal  doses.  Three  patients  with
new  parenchymal  lesions  were  receiving
steroids and ATb treatment at the time of the
second  MRI,  despite  steroids,  an  immune
reconstitution  syndrome  was  suspected.  The
correlation between clinical the characteristics
and outcome is described in Table 2.
Univariate  analysis  showed  a  statistically
significant  relation  between  neurological
sequelae and a positive CSF culture (P=0.001).
There was a tendency in the relation between
the neurological sequelae and a time interval
longer  than  10  days  between  symptoms  and
treatment  (P=0.087),  neurological  sequelae
and  clinical  stage  II  (P=0.092)  and  clinical
stage III (P=0.071) at the time of initiating
treatment. Notably, neither age above 50 years
old,  meningeal  or  cerebral  presentation  at
onset, Glasgow Coma Scale (GCS) at onset, or
HIV  co-infection  were  associated  with  the
development of neurological sequelae. Death
was significantly associated with a treatment
lag of more than 10 days (P=0.002), and there
was  a  tendency  between  death  and  clinical
stage  III  at  the  time  of  initiating  treatment
(P=0.051)  and  between  death  and  HIV  co-
infection  (P=0.077).  Multivariate  analysis
showed that a GCS at entry below 10 points
(P=0.001), and the clinical stage III at entry
(P=0.001), were significantly associated with
death. The isolation of M. bovis was signifi-
cantly  associated  with  cerebral  lesions
(P=0.032),  and  neurological  sequelae
(P=0.020) in the univariate and multivariate
analysis.
Discussion
Central  nervous  system  involvement  was
found in 30% of the patients with M. tuberculo-
sis infection, considerably higher than the 5%
to 10% observed in other series.2 Table 2 com-
pares  the  most  relevant  characteristics
between this series and other similar series.
As shown before, worse outcomes were related
to the later clinical presentation and the delay
in initiating treatment. The most common fac-
tor for delaying the treatment was the suspi-
cion  of  bacterial  meningitis.  Other  studies3
have also observed that the medical delay is
usually  associated  with  the  use  of  empiric
antibiotics. 
Previous studies have already pointed out
the  value  of  adenosine  deaminse  (ADA)
enzyme determination in the CSF for the diag-
nosis of Mtb7,8 When a cutoff value of 10 UI
was used, ADA showed a sensitivity of 92.7%
and specificity of 97% for the early diagnosis of
CNS tuberculosis.8 In this study, ADA determi-
nation persisted as a valuable tool for support-
ing the diagnosis. Moreover, the median value
of ADA in this study was 8 UI, which is consis-
tent with other studies.7 On the other hand,
the effectiveness of the polymerase chain reac-
tion (PCR) for CNS tuberculosis continues to
be highly controversial. Although sensitivity is
considered around 45% and specificity is 92%,9
previous  studies  in  Mexico  showed  a  much
higher a sensitivity of 75% with a specificity of
59%.9 In this study, PCR was positive only in 22
(55%)  of  40  patients.  Our  findings  supports
those of Rana et al. 8 who reports that CSF ADA
determination  is  a  more  sensitive  indicator
than PCR for the diagnosis of CNS tuberculo-
sis.8 CSF culture was positive in 18(28%) and
only 3(4.6%) of the bacillus was found by CSF
staining. However, when other tissues and flu-
Article
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Table 1. Main characteristics at onset and follow-up between patients.
Onset Follow-up
Clinical findings (n=64) Not relevant
CGS <15 points 43(66%)
Aphasia 4(6%)






Severe neurological deterioration NA 31 (48%)
Radiological findings (n=49) (n=28)
Hydrocephalus 6 (9.4%) 6 (21.4%)
Meningeal enhancement 13 (20.3%) 3 (10.7%)
Parenquimatous lesions 21 (32.8%) 5 (17.8%)
Stroke 9 (14.1%) 6 (21.4%)
Same or improvement 8(28.5%)
Lumbar puncture (n=55) (n=32)
Proteins (mg/dL) 172 mg/dL 550 mg/dL
(Mean)
Glucose (mg/dL) 39 mg/dL 48 mg/dL
Cells (cells/mm3) 102 cel/mm3 90 cel/mm3
(Mean)
SD, standard deviation.
Table 2. Comparison of the principal characteristics between similar series.
Series
Variable Sutlas  Misra  Saitoh  Sheu México
(Turquia) (India) (California) (Taiwán) (n=64)
(n=61) (n=54) (n=20) (n=105)
Clinical stage
I0 9 (16.6%) 4(20%) 37(35.2%) 11 (17.2%)
II 44% 12 (22-2%) 6(30%) 68(64.8%) 26 (40.6%)
III 56% 33 (61.1%) 10(50%) 0 27 (42.2%)
Interval ≈onset  2d-5m NA 8-14d(45%) 1-120d  0-60
to admission (mean) (29 days) >15d (30%) (10 days) (30 days)
Interval ≈admission  NA NA 1-8 0-81 0-540
to Atb (mean) (1 day) (5 days) (21 days)
Hidrocephalus 14 (23%) 29 (53.7%) 13 (68%) 37(35.2%) 12(18.7%)
Tuberculomas 21 (34%) 12(22.2%) 11 (58%) 7(6.6%) 26(40.6%)
Isquemic Stroke 13 (21%) 25(46.2%) 29 (27%) 19(29%)
Neurological sequelae 19(31%) NA 7(35%) 69 (65.7%) 24(37%)
Seizures 10(16%) 17(31.8%) 3(15%) NA 29(45.3%)
Death 17 (27.8%) NA 1(5%) 15(14.3%) 23(35%)
Prognostic factors  Stage II-III Focal wk None OT >5d OT >10d
for worse outcome GCS<6 Stage prg. HIV +
SSEP M. bovis
Stage III
GCS, Glasgow Coma Scale; SSEP, Somatosensory evoked potentials; OT, onset of treatment; WK, weakness; PGR, progression.ids were tested, isolation of the mycobacteri-
um increased to 84% by culture and 12.5% by
staining, even when the patient had no obvi-
ous systemic manifestations. 
Of  particular  relevance  was  the  fact  that
15%  of  the  CSF  cultures  showed  M.  bovis
growth. The worldwide frequency, pathogene-
sis  or  mode  of  transmission  of  the  bovine
agent infection in humans is not known. It is
possible that despite strict sanitary measures,
its frequency is higher than estimated, espe-
cially in developing countries where there is a
lack of strict control in livestock.10,11 Notably,
none of the Asian studies mentioned the pres-
ence  of  M.  bovis.  However,  Saitoh  et  al.6
showed 3 out of 20 of their patients had posi-
tive cultures for M. bovis. It is worth mention-
ing that in their study almost all the patients
had  a  Hispanic  ancestry,  and  most  lived  in
Mexico or in the border between Mexico and
the United States. While the mode of transmis-
sion is uncertain, some of our patients recog-
nized the ingestion of raw milk. Reactivation
from previous childhood exposure and human
to human transmission are possible, but the
absence  of  extrapulmonary  disease,  the
absence of contact between affected cases and
the poor differentiation of the genotypes sug-
gest that the most common cause of transmis-
sion  in  these  cases  was  through  the  recent
ingestion of contaminated dairy products.
More importantly, M. bovis was associated
with a worse prognosis, including the presence
of tuberculomas (P=0.032), the need for neu-
rosurgery (0.074), and an increased frequency
of neurologic sequelae (P=0.023). The associ-
ation  of  a  worse  prognosis  underscores  the
importance  of  further  classifying  the  sub-
species in all patients with a positive culture
for  M.  tuberculosis,  especially  in  patients  in
which there is no improvement despite treat-
ment.10 There is no obvious reason to explain
the worse prognosis since the recommended
treatment is identical for both subspecies, but
there is a possibility that these species differ
in their mechanisms of the immune response
evasion or that the pathogenesis is different.
Another relevant finding was that more than
80% of the patients had neurological manifes-
tations at onset of the systemic disease. This
finding suggests that tuberculosis in the CNS
is not a more severe form of pulmonary tuber-
culosis, but rather a primary phenomenon, or
at least with a simultaneous occurrence to the
pulmonary disease. It is possible that M. tuber-
culosis organisms with predilection to the CNS
comprise  different  characteristics  in  patho-
genesis or species.12
Our conclusions are limited for a number of
reasons. First, the retrospective nature of the
information is limited to what it is documented
in  the  medical  records,  and  the  neurological
examinations are usually not rigorous and are
subject  to  variations  between  examiners.
Second,  there  are  no  standardized  protocols
that agree in the optimal time for initiation of
medical  or  surgical  treatment,  variables  that
have  an  enormous  impact  in  the  outcome.
There were also important differences between
the  time  and  number  of  diagnostic  ancillary
tests,  lumbar  puncture  PCR,  ADA  determina-
tion, etc. For example, the tuberculin test was
not  as  frequently  performed  as  we  expected,
possibly  due  its  poor  predictive  value  in  an
endemic area. Lastly, our Center is a tertiary
hospital, which may concede a selection bias in
the rates and severity of the disease.
Conclusions
In our series, the neurologic manifestations
of M. tuberculosis infection occurred isolated
or simultaneous to the onset of the systemic
manifestations.  CSF  Adenosin  deaminase
determination was a more sensitive method
for the early diagnosis than PCR for M. tuber-
culosis. The isolation of M. bovis subspecies
was  associated  with  worse  prognosis.
Initiating empirical treatment with antibiotics
for the suspicion of bacterial meningitis was
the principal cause of delay for the initiation of
anti-tuberculosis treatment and consequently
for a poor outcome. Further research is needed
to differentiate M. tuberculosis with predilec-
tion for the CNS from other organisms that do
not cause CNS involvement. 
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